



Amendments to the Claims:

1.(Currently amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



in which R^a is a group of formula (i)




wherein P¹ is phenyl, naphthyl, or heteroaryl an aromatic ring containing 1 to 3 heteroatoms selected from the group consisting of O, N and S, or pyrazolyl;

R¹ is halogen, C₁-6alkyl, C₃-6cycloalkyl, COC₁-6alkyl, C₁-6alkoxy, hydroxy, hydroxyC₁-6alkyl, nitro, CF₃, cyano, SR⁶, SOR⁶, SO₂NR⁶R⁷, CO₂R⁶, CONR⁶R⁷, OCONR⁶R⁷, NR⁶R⁷, NR⁶CO₂R⁷, NR⁶CONR⁷R⁸, CR⁶=NOR⁷ where R⁶, R⁷ and R⁸ are independently hydrogen or C₁-6alkyl;

a is 0, 1, 2 or 3;

or R^a is a group of formula (ii)



wherein

P² is phenyl, naphthyl, or heteroaryl or a 5 to 7 membered heterocyclic ring which is an aromatic ring containing 1, 2 or 3 heteroatoms selected from the group consisting of O, N, and S;

P^3 is phenyl, naphthyl or heteroaryl which is an aromatic ring containing 1, 2 or 3 heteroatoms selected from the group consisting of O, N, and S;

A is a bond or oxygen, carbonyl, CH_2 or NR^4 where R^4 is hydrogen or C_{1-6} alkyl;

R^2 is as defined above for R^1 in formula (i) or R^2 is heteroaryl optionally substituted by C_{1-6} alkyl, halogen or COC_{1-6} alkyl or is a 5 - 7 membered heterocyclic ring optionally substituted by oxo;

R^3 is halogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} alkoxy, COC_{1-6} alkyl, hydroxy, nitro, CF_3 , cyano, CO_2R^6 , $CONR^6R^7$, NR^6R^7 where R^6 and R^7 are as defined above;

b and c are independently 0, 1, 2 or 3;

Y is a single bond, CH_2 , O or NR^5 where R^5 is hydrogen or C_{1-6} alkyl;

W is $-(CR^9R^{10})_t-$ where t is 2, 3 or 4 and R^9 and R^{10} are independently hydrogen or C_{1-6} alkyl or W is a group $-CH=CH-$;

R^b is hydrogen, halogen, hydroxy, C_{1-6} alkyl, CF_3 , COC_{1-6} alkyl, cyano or C_{1-6} alkoxy;

R^c is hydrogen or C_{1-6} alkyl; and

R^d and R^e are independently C_{1-4} alkyl.

2.(Original) A compound according to claim 1 in which R^a is a group of formula (i) wherein P^1 is phenyl.

3.(Original) A compound according to claim 2 in which R^1 is halogen, C_{1-6} alkyl, nitro, CF_3 or cyano.

4.(Previously Amended) A compound according to claim 1 in which Y is CH_2 .

5.(Original) A compound according to claim 1 in which R^a is a group of formula (ii) wherein A is a single bond, P^3 is phenyl or naphthyl and P^2 is phenyl, pyridyl, pyrazinyl, oxadiazolyl, oxazolyl or piperidinyl.

6.(Previously Amended) A compound according to claim 1 in which W is $-CH_2-CH_2-$ or $-CH=CH-$.

7.(Previously Amended) A compound according to claim 1 in which R^c is hydrogen or methyl.

8.(Previously Amended) A compound according to claim 1 in which R^d and R^e are both methyl.

9. (Currently Amended) A compound according to claim 1 which is

cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

Serial No.: 10/802,236
Group Art Unit No.: 1624

cis-5-methoxy-1-[5-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[5-(2-methyloxazol-5-yl)-1-naphthoyl]-6-(3,4,5- trimethylpiperazin-1-yl)indoline,

cis-1-(2,3-dichlorobenzoyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[(3-nitrophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-6-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-1,2,3,4-tetrahydro-7-(3,4,5-trimethylpiperazin-1-yl)quinoline ,

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-dichlorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-difluorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-dichlorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-dichlorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-difluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylacetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-chloro-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[4-(2,6-dimethylpyridin-3-yl)-1-naphthoyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[4-(3,6-dimethylpyrazin-2-yl)-1-naphthoyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

~~*cis*-5-methoxy-1-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline;~~

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-chloro-3-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-bromo-3-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

Serial No.: 10/802,236
Group Art Unit No.: 1624

cis-1-[(2-bromo-3-chlorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-fluoro-2-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-chloro-2-cyanophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-Acetyl-3-chlorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-bromo-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-cyano-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-bromo-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-Acetyl-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[(2-phenyl-3-(trifluoromethyl)pyrazol-4-ylcarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-6-(3,5-dimethylpiperazin-1-yl)-1-[(4-(2,5-dimethylpyridin-4-yl)benzoyl]-5-methoxyindoline,

cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[2'-methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]indoline,

cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(2-methyl-6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)benzoyl]-indoline, •

cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]indoline,

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-5-cyano-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-aminocarbonyl-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

Serial No.: 10/802,236
Group Art Unit No.: 1624

cis-5-methoxy-1-[4-(1-methylpiperidin-4-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,) *cis*-5-methoxy-1-[4-(piperidin-4-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole, *cis*-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indole, *cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indole, *cis*-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylacetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole, *cis*-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindole, *cis*-1-[(2,3-dichlorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindole, *cis*-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indole, *cis*-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-5-methoxy-1-[5-(6-methylpyridin-2-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-5-methoxy-1-[5-(2-methyloxazol-5-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-(3-chloro-2-fluorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-[3-fluoro-2-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-[2-chloro-3-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-[2-chloro-3-methylphenyl)aminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-[2-chloro-3-(trifluoromethyl)phenyl)aminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-(2,3-dichlorophenylaminocarbonyl)-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-chloro-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-bromo-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-ethyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

Serial No.: 10/802,236
Group Art Unit No.: 1624

cis-5-methoxy-1-[2-(trifluoromethyl)phenylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[2-fluoro-3-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[2-chloro-3-(trifluoromethyl)phenylaminocarbonyl]-3,3-dimethyl-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-chloro-3-trifluoromethyl)phenoxy carbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

or a pharmaceutically acceptable salt thereof.

10. (Currently Amended) A compound according to claim 1 which is

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

or *cis*-1-[(2,3-dichlorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline

cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(2-methyl-6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)benzoyl]-indoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindole,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indole, or

cis-1-[2-chloro-3-(trifluoromethyl)phenyl)aminocarbonyl]-5-methyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

or a pharmaceutically acceptable salt thereof.


11. (Currently Amended) A process for the preparation of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof which comprises:

(a) where Y is NH, coupling a compound of formula (II):




(II)

in which R^a is as defined in formula (I) with a compound of formula (III):




in which W, R^b, R^c, R^d and R^e are as defined in formula (I); or

(b) — where Y is NR⁵, reacting a compound of formula (IV)



in which R^a and R⁵ are as defined in formula (I) with a compound of formula (III) as defined above together with an appropriate urea-forming agent; or

(eb) where Y is a single bond, CH₂ or O, reacting a compound of formula (V)



in which R^a is as defined in formula (I) and L is an appropriate leaving group, with a compound of formula (III) as defined above;

and optionally thereafter for process (a), (b) or (c):

- removing any protecting groups,
- converting a compound of formula (I) into another compound of formula (I),
- forming a pharmaceutically acceptable salt.

12 - 13.(Cancelled)

14. (Previously Amended) A pharmaceutical composition which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

15 - 16. (Cancelled).

17. (New) A method for treating depression in a mammal suffering same, which method comprises administering a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thererof alone or in admixture with a pharmaceutically acceptable carrier or excipient.
18. (New) A compound which is is *cis*-5-methoxy-1-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline or a pharmaceutically acceptable salt hereof.